Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00087) | |||||
---|---|---|---|---|---|
Name |
Cabozantinib
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Cabozantinib; 849217-68-1; Cometriq; XL-184; BMS-907351; XL 184; BMS 907351; Cabozantinib (XL184, BMS-907351); UNII-1C39JW444G; CHEBI:72317; XL-184 free base; BMS907351; 1C39JW444G; MFCD20926324; Cabometyx (TN); Cometriq (TN); Cabozantinib (XL-184); 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE; C28H24FN3O5; n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide; N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; Cabozantinib [USAN:INN]; N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; XL184 free base; Cabozantinib/XL184; Cabozantinib (USAN); PubChem22994; Cabozantinib (free base); SCHEMBL360795; GTPL5887; CHEMBL2105717; DTXSID10233968; EX-A075; QCR-122; SYN1138; XL184 free base - Cabozantinib; BCPP000308; BMS-907351 FREE BASE; HMS3654G06; XL-184 free base (Cabozantinib); AOB87755; BCP02591; 849217-68-1 (free base); ABP000796; BDBM50021574; NSC761068; NSC800066; ZINC70466416; AKOS025142112; BCP9000470; CCG-264678; CS-0278; DB08875; NSC-761068; NSC-800066; SB20062; XL-184 (Cabozantinib,BMS907351); XL-184,Cabozantinib, BMS-907351; NCGC00263164-01; NCGC00263164-14; NCGC00263164-17; 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-; 1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-; AC-25082; AS-16277; HY-13016; SY097158; AB0033751; DB-023624; FT-0664184; SW218093-3; D10062; Q-3907; AB01565831_02; Q795057; SR-01000941569; J-523016; SR-01000941569-1; BRD-K51544265-001-01-8; 1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-; cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide; cyclopropane-1,1-dicarboxylic acid[4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide; N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide; N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; N-[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]-N inverted exclamation mark -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Thyroid cancer | ICD-11: 2D10 | [1] | ||
PubChem CID | |||||
Formula |
C28H24FN3O5
|
||||
Canonical SMILES |
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
|
||||
InChI |
1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
|
||||
InChIKey |
ONIQOQHATWINJY-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=25102847"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 501.5 | Topological Polar Surface Area | 98.8 | |
XlogP | 5.4 | Complexity | 795 | ||
Heavy Atom Count | 37 | Rotatable Bond Count | 8 | ||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Cabozantinib 20 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Stearic acid; Butyl alcohol; Isopropyl alcohol; Ammonia; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Gelatin; Shellac; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Exelixis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Stearic acid | DIG Info | Phosphodiesterase 3A (IC50 = 3.1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Cabozantinib S-Malate eq 80mg base capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Silicified Microcrystalline Cellulose; Croscarmellose Sodium; Sodium Starch Glycolate; Fumed Silica; Stearic Acid; Shellac Glaze; Black Iron Oxide; N-Butyl Alcohol; Isopropyl Alcohol; Propylene Glycol; Ammonium Hydroxide; Red Iron Oxide; Titanium Dioxide
|
|||||
Dosage Form | Capsule | |||||
Company | Exelixis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Stearic acid | DIG Info | Phosphodiesterase 3A (IC50 = 3.1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Cabozantinib S-Malate eq 20mg base capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Silicified Microcrystalline Cellulose; Croscarmellose Sodium; Sodium Starch Glycolate; Fumed Silica; Stearic Acid; Shellac Glaze; Black Iron Oxide; N-Butyl Alcohol; Isopropyl Alcohol; Propylene Glycol; Ammonium Hydroxide; Titanium Dioxide
|
|||||
Dosage Form | Capsule | |||||
Company | Exelixis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Stearic acid | DIG Info | Phosphodiesterase 3A (IC50 = 3.1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Cabozantinib S-Malate eq 20mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Microcrystalline Cellulose; Lactose Anhydrous; Hydroxypropyl Cellulose; Croscarmellose Sodium; Colloidal Silicon Dioxide; Magnesium Stearate; Hypromellose; Titanium Dioxide; Triacetin; Iron Oxide Yellow
|
|||||
Dosage Form | Tablet | |||||
Company | Exelixis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Hydroxypropyl cellulose | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 89.5 uM) | [6] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [6] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Cabozantinib S-Malate eq 40mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Microcrystalline Cellulose; Lactose Anhydrous; Hydroxypropyl Cellulose; Croscarmellose Sodium; Colloidal Silicon Dioxide; Magnesium Stearate; Hypromellose; Titanium Dioxide; Triacetin; Iron Oxide Yellow
|
|||||
Dosage Form | Tablet | |||||
Company | Exelixis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Hydroxypropyl cellulose | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 89.5 uM) | [6] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [6] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Cabozantinib S-Malate eq 60mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Microcrystalline Cellulose; Lactose Anhydrous; Hydroxypropyl Cellulose; Croscarmellose Sodium; Colloidal Silicon Dioxide; Magnesium Stearate; Hypromellose; Titanium Dioxide; Triacetin; Iron Oxide Yellow
|
|||||
Dosage Form | Tablet | |||||
Company | Exelixis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Hydroxypropyl cellulose | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 89.5 uM) | [6] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [6] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Cabozantinib 20 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Triacetin; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type h); Hypromelloses
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Exelixis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Cabozantinib 40 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Triacetin; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type h); Hypromelloses
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Exelixis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Cabozantinib 60 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Triacetin; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type h); Hypromelloses
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Exelixis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.